Ren Ding, Cheng Hao, Wang Xin, Vishnoi Monika, Teh Bin S, Rostomily Robert, Chang Jenny, Wong Stephen T, Zhao Hong
Outpatient Department, PLA Navy NO.905 Hospital, Shanghai, P.R. China.
Department of Orthopedics, Tongji Hospital, Wuhan, P.R. China.
Ther Adv Med Oncol. 2020 Jun 30;12:1758835920936151. doi: 10.1177/1758835920936151. eCollection 2020.
Systemic therapies for primary breast cancer have made great progress over the past two decades. However, oncologists confront an insidious and particularly difficult problem: in those patients with metastatic breast cancer, up to 50% of human epidermal growth factor 2 (HER2)-positive and 25-40% of triple-negative subtypes, brain metastases (BM) kill most of them. Fortunately, standard- of-care treatments for BM have improved rapidly, with a decline in whole brain radiation therapy and use of fractionated stereotactic radiosurgery as well as targeted therapies and immunotherapies. Meanwhile, advances in fundamental understanding of the basic biological processes of breast cancer BM (BCBM) have led to many novel experimental therapeutic strategies. In this review, we describe the most recent clinical treatment options and emerging experimental therapeutic strategies that have the potential to combat BCBM.
在过去二十年中，原发性乳腺癌的全身治疗取得了巨大进展。然而，肿瘤学家面临着一个隐匿且特别棘手的问题：在那些转移性乳腺癌患者中，高达50%的人表皮生长因子2（HER2）阳性亚型以及25%-40%的三阴性亚型患者会因脑转移（BM）而死亡。幸运的是，BM的标准治疗方法已迅速改进，全脑放射治疗减少，分次立体定向放射外科以及靶向治疗和免疫治疗的使用增加。与此同时，对乳腺癌脑转移（BCBM）基本生物学过程的深入理解取得进展，催生了许多新的实验性治疗策略。在本综述中，我们描述了最新的临床治疗选择以及有可能对抗BCBM的新兴实验性治疗策略。
